ClinicalTrials.gov
public full text
Public Domain
Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
This study assessed the long term safety data for the use of tobramycin inhalation powder in patients suffering from cystic fibrosis who have a chronic pulmonary infection with Pseudomonas aeruginosa.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis#915333
- Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis#873021
- An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis#844875
- Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease#1111758
- A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo#1088039
Record · ID 1046410
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive